Your source of breaking information about Dutasteride also known as Avodart, Avolve, GI198745, GG745 or Duagen.
dutasteride duagen avodart avolve 
  Dutasteride.org is an independent clearinghouse for information about Dutasteride and is not associated or affiliated with GlaxoSmithKline or the Glaxo Group Limited. Avolve, Avodart and Duagen are registered trademarks of Glaxo Group Limited.  


What is Dutasteride

The Latest News

Dutasteride Studies

Dutasteride Safety Profile

FDA Approval Documents

Dutasteride Results


If you are interested in getting more information via email about the availability of Avodart please enter your email address below

hair loss MPB Dutasteridedutastiride avolve duagen
 
Safety Profile
 
 
DUTASTERIDE PHASE 3 BPH TRIAL
SIDE EFFECTS
Dose - 0.5 mg

Side Effect Observed Placebo (N=2158)  Actual Drug (N=2166)
Impotence 59 (3%) 117 (5%)
Decreased Libido 40 (2%) 74 (3%)
Ejaculation Disorders 14 (<1%) 40 (2%)
Gynecomastia 10 (<1%) 29 (1%)
   
The Phase III BPH trials for Dutasteride were conducted on 4300 male subjects between the ages of 47 and 94 years old, 90% of them being Caucasian. The average age was 66 years old and the participants received either a placebo or a 0.5mg daily dose of Dutasteride. 2158 men received the placebo and 2166 of the men received Dutasteride. A total of 267 subjects (6% of each treatment group) were withdrawn from the studies due to adverse experiences, usually associated with the reproductive system. Withdrawal due to adverse events considered by the investigators to have a reasonable possibility of being caused by the medication occurred in 3% of the subjects receiving Dutasteride and in 2% of the subjects receiving the placebo.
 
lowers DHT and promotes hair regrowth
Glaxo sells Avodart also know as Dutasteride   Avolve Avodart  GI198745  Duagen
 
  Copyright © 2002 Interactive Marketing Group - All Rights Reserved - email: info@dutasteride.org